NICE Guideline: COVID-19 rapid guideline: delivery of systemic anticancer treatments

NICE | March  2020 |COVID-19 rapid guideline: delivery of systemic anticancer treatments

NICE guideline [NG161]

The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

On 3 April 2020, NICE added 2 recommendations on when to offer and continue systemic anticancer treatment for patients with COVID-19. NICE also amended the table on prioritising treatments in line with new advice from NHS England.

 

This guideline is for:

  • health and care practitioners
  • health and care staff involved in planning and delivering services
  • commissioners

Further information availlable from NICE 

NICE has also produced a COVID-19 rapid guideline on delivery of radiotherapy.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s